Eli Lilly Agrees To Acquire Sigilon Therapeutics
Portfolio Pulse from Benzinga Newsdesk
Eli Lilly has agreed to acquire Sigilon Therapeutics. The deal involves a tender offer to acquire all outstanding shares of Sigilon for $14.92 per share in cash, plus one non-tradeable contingent value right per share that could add up to an additional $111.64 per share in cash. The total potential consideration could reach up to $126.56 per share in cash, amounting to approximately $309.6 million excluding shares held by Lilly.
June 29, 2023 | 10:50 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Eli Lilly's acquisition of Sigilon Therapeutics could potentially strengthen its portfolio and market position.
Acquisitions often provide companies with opportunities to expand their product portfolio and market reach. This acquisition could potentially strengthen Eli Lilly's position in the market.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Sigilon Therapeutics shareholders stand to gain from the acquisition by Eli Lilly, with a potential total consideration of up to $126.56 per share in cash.
The acquisition deal offers a significant cash consideration for Sigilon Therapeutics shareholders, which could potentially lead to a positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100